Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mycophenolate mofetil in lupus nephritis.

E M Ginzler1, C Aranow

  • 1Department of Medicine, SUNY-Downstate Medical Center, Brooklyn, NY 1203, USA. ellen.ginzler@downstate.edu

Lupus
|March 1, 2005
PubMed
Summary

Mycophenolate mofetil (MMF) is an effective and well-tolerated treatment for lupus nephritis. Studies show MMF offers comparable efficacy to cyclophosphamide with fewer infections, presenting a viable alternative standard of care.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IFN-associated B cell hyperactivity is highly enriched in SLE patients harboring Sm/RNP antibodies.

bioRxiv : the preprint server for biology·2024
Same author

Alterations in Blood-Brain Barrier Permeability in Patients with Systemic Lupus Erythematosus.

AJNR. American journal of neuroradiology·2019
Same author

Dynamic Contrast-Enhanced MRI Reveals Unique Blood-Brain Barrier Permeability Characteristics in the Hippocampus in the Normal Brain.

AJNR. American journal of neuroradiology·2019
Same author

The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients.

Lupus·2017
Same author

Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients.

Arthritis care & research·2017
Same author

Breast cancer in systemic lupus.

Lupus·2016

Area of Science:

  • Nephrology
  • Immunology
  • Pharmacology

Background:

  • Lupus nephritis is a severe complication of systemic lupus erythematosus.
  • Current treatments like corticosteroids and cyclophosphamide have limitations.
  • Mycophenolate mofetil (MMF) shows promise as an alternative immunosuppressive therapy.

Purpose of the Study:

  • To review existing data on MMF in lupus nephritis.
  • To evaluate MMF's efficacy and tolerability compared to standard treatments.
  • To assess MMF as a potential standard of care for lupus nephritis.

Main Methods:

  • Review of literature on MMF in murine lupus models.
  • Analysis of anecdotal clinical experience in human lupus nephritis.
  • Examination of results from nonblinded, controlled clinical trials comparing MMF and cyclophosphamide.

Main Results:

  • MMF demonstrated efficacy in murine lupus models, improving renal function and survival.
  • Clinical trials indicated MMF is well-tolerated in human lupus nephritis patients.
  • MMF showed comparable efficacy to cyclophosphamide with a lower incidence of infections.

Conclusions:

  • Mycophenolate mofetil (MMF) is a safe and effective treatment option for lupus nephritis.
  • MMF offers an alternative standard of care for induction and maintenance therapy.
  • MMF provides a favorable risk-benefit profile compared to cyclophosphamide.

Related Experiment Videos